Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

This publication has 17 references indexed in Scilit:

• Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib
  Leukemia Research, 2004
• Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
  Leukemia, 2003
• Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
  The Lancet, 2003
• Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
  Blood, 2003
• Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
  Leukemia, 2002
• Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia
  Acta Haematologica, 2002
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
  Blood, 2001
• Characteristics of accelerated disease in chronic myelogenous leukemia
  Cancer, 1988